Cargando…

Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer

BACKGROUND: Despite benefits of endocrine therapy (ET) for patients with hormone-receptor (HR)-positive breast cancer, many patients do not initiate or discontinue ET against recommendations. METHODS: We identified variables associated with ET initiation and continuation, analyzing pooled data from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Beomyoung, Pérez, Maria, Jeffe, Donna B., Kreuter, Matthew W., Margenthaler, Julie A., Colditz, Graham A., Liu, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341086/ https://www.ncbi.nlm.nih.gov/pubmed/35915419 http://dx.doi.org/10.1186/s12885-022-09946-x

Ejemplares similares

Association of Endocrine Therapy Initiation Timeliness With Adherence and Continuation in Low-Income Women With Breast Cancer
por: Sood, Nikita, et al.
Publicado: (2022)

Hormone Replacement Therapy, Likely Neither Angel Nor Demon
por: Wachtel, Mitchell S., et al.
Publicado: (2015)

Menopausal hormone therapy after breast cancer
por: Colditz, Graham A
Publicado: (2005)

Shifts in endocrine homeostasis and preventive hormone replacement therapy: extending the Women’s Health Initiative globally
por: Ball, Jacob D., et al.
Publicado: (2016)

Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
por: D’Souza, Anishka, et al.
Publicado: (2018)

Safety of adjuvant endocrine therapies in hormone receptor–positive early breast cancer
por: Sehdev, S., et al.
Publicado: (2009)

Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
por: Rani, Aradhana, et al.
Publicado: (2019)

Surgery Should Complement Endocrine Therapy for Elderly Postmenopausal Women with Hormone Receptor-Positive Early-Stage Breast Cancer
por: Nguyen, Olivier, et al.
Publicado: (2012)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor–Positive, ERBB2-Negative Breast Cancer
por: Ma, Sung Jun, et al.
Publicado: (2020)

Hormone and receptor activator of NF-κB (RANK) pathway gene expression in plasma and mammographic breast density in postmenopausal women
por: Mintz, Rachel, et al.
Publicado: (2022)

An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor– positive early breast cancer
por: Verma, S., et al.
Publicado: (2009)

Short-term weight gain and breast cancer risk by hormone receptor classification among pre- and postmenopausal women
por: Rosner, Bernard, et al.
Publicado: (2015)

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
por: Bian, Li, et al.
Publicado: (2020)

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer
por: Yuan, Jie, et al.
Publicado: (2023)

Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
por: López González, Ana, et al.
Publicado: (2022)

Chromogranin A‐positive hormone‐negative endocrine cells in pancreas in human pregnancy
por: Moin, Abu Saleh Md, et al.
Publicado: (2021)

Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer
por: Hu, Xin, et al.
Publicado: (2022)

The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor‐positive breast cancer: A single‐institute retrospective study
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Exosc9 Initiates SUMO-Dependent lncRNA TERRA Degradation to Impact Telomeric Integrity in Endocrine Therapy Insensitive Hormone Receptor-Positive Breast Cancer
por: Quttina, Maram, et al.
Publicado: (2023)

Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis
por: Lee, Cho-Hao, et al.
Publicado: (2020)

RETRACTION: Challenges of Combined Everolimus/Endocrine Therapy in Hormone Receptor-Positive Metastatic Breast Cancer
por: Porta, Camillo
Publicado: (2014)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Predictors of full-time faculty appointment among MD–PhD program graduates: a national cohort study
por: Andriole, Dorothy A., et al.
Publicado: (2016)

Endocrine therapy initiation and overall survival outcomes with omission of radiation therapy in older Medicare patients with early‐stage hormone‐receptor‐positive breast cancer
por: Shen, Chan, et al.
Publicado: (2022)

Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer
por: Kantor, Olga, et al.
Publicado: (2020)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
por: Nabieva, Naiba, et al.
Publicado: (2023)

Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women
por: Pritchard, Kathleen
Publicado: (2005)

This is the Moment…
por: Margenthaler, Julie A.
Publicado: (2022)

Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naïve Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
por: Telford, Claire, et al.
Publicado: (2019)

Cost-effectiveness of Tamoxifen, Aromatase Inhibitor, and Switch Therapy (Adjuvant Endocrine Therapy) for Breast Cancer in Hormone Receptor Positive Postmenopausal Women in India
por: Butani, Dimple, et al.
Publicado: (2021)

Hormone Production in Endocrine Tumours
por: Abelson, Denis
Publicado: (1958)

An Increase in Chromogranin A-Positive, Hormone-Negative Endocrine Cells in Pancreas in Cystic Fibrosis
por: Cory, Megan, et al.
Publicado: (2018)

Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer
por: Bahnassy, Shaymaa, et al.
Publicado: (2020)

Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis
por: Liao, Hao, et al.
Publicado: (2022)

Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System
por: Guarnotta, Valentina, et al.
Publicado: (2022)

Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
por: Kim, Jisun, et al.
Publicado: (2012)

The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy
por: Oner, Gizem, et al.
Publicado: (2023)

Perturbation of Nuclear Hormone Receptors by Endocrine Disrupting Chemicals: Mechanisms and Pathological Consequences of Exposure
por: Hall, Julie M., et al.
Publicado: (2019)

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer
por: Foldi, Julia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6d30prpb3qcg0gae09c6q3jd0s